Evidence map›Paper›PMID 35157511›Full record

ArticleJCO global oncology2022

Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria.

Adedayo Joseph, Bankole Olatosi, Mohammad Rifat Haider, Bolanle C Adegboyega, Nwamaka N Lasebikan, Usman M Aliyu, Musa Ali-Gombe, Mutiu A Jimoh, Olusegun Abayomi Biyi-Olutunde, Opeyemi Awofeso and 10 more

Abstract read
In one paragraph

Article in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. COVID-19 impacts on healthcare access in sub-Saharan Africa: an overview.The journal of venomous animals and toxins including tropical diseases · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Adedayo JosephNSIA-LUTH Cancer Center, Lagos University Teaching Hospital, Lagos, Nigeria.ORCID 0000-0002-7938-1218
Bankole OlatosiHealth Services, Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC.ORCID 0000-0002-8295-8735
Mohammad Rifat HaiderDepartment of Health Policy and Management, College of Public Health, University of Georgia, Athens, GA.ORCID 0000-0002-0690-8242
Bolanle C AdegboyegaNSIA-LUTH Cancer Center, Lagos University Teaching Hospital, Lagos, Nigeria.ORCID 0000-0001-5208-8073
Nwamaka N LasebikanUniversity of Nigeria Teaching Hospital, Enugu, Nigeria.ORCID 0000-0002-3775-0492
Usman M AliyuUsman Danfodiyo University Teaching Hospital, Sokoto, Nigeria.
Musa Ali-GombeFederal Teaching Hospital, Gombe, Nigeria.ORCID 0000-0002-4431-7777
Mutiu A JimohUniversity College Hospital, Ibadan, Oyo, Nigeria.ORCID 0000-0002-6383-3961
Olusegun Abayomi Biyi-OlutundeUniversity of Port-Harcourt Teaching Hospital, Port-Harcourt, Rivers State, Nigeria.
Opeyemi AwofesoLagos University Teaching Hospital, Idiaraba, Lagos, Nigeria.ORCID 0000-0002-6233-4642
Omolara Aminat FatiregunDepartment of Radiology, Lagos State University Teaching Hospital (LASUTH), Lagos, Nigeria.ORCID 0000-0001-9219-9069
Evaristus Oseiwe ObohUniversity of Benin Teaching Hospital, Edo, Nigeria.
Emmanuella NwachukwuNational Hospital, Abuja, Federal Capital Territory, Nigeria.
Ismail H ZubairuAhmadu Bello University Teaching Hospital, Kaduna, Nigeria.ORCID 0000-0002-3661-3250
Samuel A OteneFederal Medical Centre, Makurdi, Borno, Nigeria.
Oluwatoyin I IyareAlex Ekwueme Federal Teaching Hospital Abakaliki, Ebonyi, Nigeria.ORCID 0000-0001-5111-9085
Temitope AnderoEko Hospital, Lagos, Nigeria.
Alabi Babatunde MusbauFederal Medical Centre, Abeokuta, Ogun, Nigeria.
Azeezat AjoseLagos University Teaching Hospital, Idiaraba, Lagos, Nigeria.ORCID 0000-0002-4491-1805
Adedayo A OnitiloDepartment of Oncology, Marshfield Clinic Health System, Marshfield, WI.ORCID 0000-0001-9185-0606

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBecause of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions in Nigeria, we surveyed oncology patients across selected public and private cancer treatment centers. MATERIALS AND

methodsParticipating in the study were 15 tertiary cancer treatment centers across 12 Nigerian states. We recruited adult patients with cancer (18+ years) on active treatment to complete a self-administered survey on cancer care during COVID-19. We conducted descriptive and multivariate data analysis using Stata 16.1.

resultsRespondents were (n = 1,072), female (65.7%), ages 18-49 years (50.3%), and married (80.7%). The top two cancers were breast and prostate. Overall, 17.3% of respondents reported disruptions to cancer care, and more than half (51.0%) reported difficulties accessing care. Changes in chemotherapy regimens or route of administration were reported in 8.4% of respondents. Odds for any disruption were highest for older patients, western states, patients with prostate cancer, and patients with two or more flu symptoms. Odds for radiotherapy cancellation were highest for older patients, those with prostate cancer, and those with medium service perception.

conclusionThis study investigated COVID-19-influenced cancer treatment disruptions in Nigeria. Patients with cancer experienced significant disruptions to cancer care. Vulnerable patients are most likely to be negatively affected. Policies and strategies aimed at minimizing service disruptions while maintaining cancer patients' safety should be a priority for all health care institutions in the COVID-19 era.

Indexed as

COVID-19NeoplasmsAdolescentAdultFemaleHumansMaleMedical OncologyMiddle AgedNigeriaPandemicsSARS-CoV-2Young Adult

Identifiers

PMID35157511
PMCPMC8853626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.